CSRxP ANALYSIS: BIG PHARMA’S PROFIT MARGINS CLIMB TO 11 TIMES GREATER THAN OTHER SECTORS IN DRUG SUPPLY CHAIN

Brand Name Drug Companies Banking Ever Higher Profits Fueled by Egregious Price Hikes, Out-of-Control Launch Prices and an Anti-Competitive Playbook That Extends Monopolies

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released its latest analysis of margins in the prescription drug supply chain today, demonstrating the brand name pharmaceutical industry continues to post profit margins significantly greater than other sectors. In the latest analysis, which includes 2025 data for the first time, the brand name pharmaceutical industry’s profit margins are 11 times greater than other sectors of the prescription drug supply chain, up from 10 times greater in CSRxP’s two previous analyses released in January 2026 and November 2024.

“Big Pharma is expanding an already staggering multiple on the scale of its profit margins compared to every other sector of the prescription drug supply chain,” said CSRxP executive director Lauren Aronson. “While pointing a finger at everyone else for high drug prices, Big Pharma continues to bank blockbuster profits fueled by price hikes outpacing inflation, increasingly out-of-control launch prices on new products and an egregious anti-competitive playbook that blocks more affordable generics and biosimilars from the market.”

“Big Pharma’s blame game rhetoric and debunked innovation excuses are designed to maintain their profit-busting, price-hiking status quo that keeps Americans locked into paying the highest prices in the world,” Aronson continued. “To effectively lower prescription drug prices for the American people, Congress and the Administration must reject Big Pharma’s false rhetoric and hold Big Pharma accountable, particularly by cracking down on the pharmaceutical industry’s egregious anti-competitive playbook.”

CSRxP’s latest analysis finds that brand name pharmaceutical manufacturers maintain profit margins far exceeding every other major sector, with average annual net income margins 11 times higher than the average across other major supply chain sectors from 2017 through 2025. The analysis found brand name pharmaceutical manufacturers’ average net income margin increased to 24.8 percent in 2025, while other sectors, including distributors, retail pharmacies, pharmacy benefit managers and health insurers, recorded margins below two percent.

CSRxP’s analysis was conducted based on publicly available financial data from company reports and filings submitted to the U.S. Securities and Exchange Commission (SEC) for calendar years 2017 to 2025.

Read the full margin analysis HERE.

Read more about Big Pharma’s debunked innovation rhetoric HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.